Drug Profile
SOR C13
Alternative Names: SOR-C13Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Soricimed Biopharma
- Class Antineoplastics; Peptides
- Mechanism of Action TRPV6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical COVID 2019 infections
- No development reported Ovarian cancer
Most Recent Events
- 23 Jun 2023 Phase I development in Solid tumours is still ongoing in USA (IV) (NCT03784677)
- 20 Jun 2023 National Cancer Institute completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03784677)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Infusion)